Article Abstract

Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?

Authors: Muhammad Abdul-Ghani, Amin Jayyous, Nidal Asaad, Sherif Helmy, Jassim Al-Suwaidi


Both microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (myocardial infarction, stroke, amputation) complications of type 2 diabetes mellitus (T2DM) are responsible for the increased morbidity, mortality and health care expenditure in T2DM patients (1,2). Thus, decreasing the risk of diabetic vascular complications will have great impact on both public health and health care expenditure.